Phase 2 N=97 Assessing Symptomatic Clinical Episodes in Depression
Major Depressive Disorder
Primary: MADRS Score - Overall Change From Baseline — 13.7; 8.8 score on a scale — p=<.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=205 Depression Attention for Women Now (The DAWN Study)
Depressive Disorder
Primary: Depression Treatment Outcome — 0.96; 1.33 units on a scale
Phase 2 N=341 A Clinical Study to Test the Effectiveness of an Investigational Drug to Treat People That Have Major Depressive Episodes When They Have Bipolar 1 Depression
Depressive Episode · Bipolar 1 Depression
Primary: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 6 — -19.485; -19.324; -16.196 units on a scale — p=0.044
N/A N=9 European Deep Brain Stimulation (DBS) Depression Study
Depressive Disorder, Major
Primary: Mean Percent Change From Baseline in MADRS Score — -7.7; -7.4; -8.8; -6.2 percentage change from baseline
N/A N=100 Supportive and Supportive-Expressive Treatment for Depression
Major Depressive Disorder
Primary: Hamilton Rating Scale for Depression (HRSD) — 12.32; 12.06; 20.20; 20.08 units on a scale — p=.016
Phase 3 N=48 Major Depressive Disorder With Mixed Features - Extension
Major Depressive Disorder
Primary: Percentage of Subjects With Treatment Emergent Adverse Events (TEAEs) — 66.7 percentage of subjects
Phase 4 N=21 Brexpiprazole for Bipolar Depression
Bipolar Depression
Primary: The Montgomery-Asberg Depression Rating Scale (MADRS) — 31.95; 9.95; 10.95 score on a scale — p=<.001
Phase 2 N=504 MDD POC Study GSK372475 Subjects Depressive Disease
Depressive Disorder
Primary: Mean Change From Randomization at the End of the Treatment Phase in the MADRS Total Score — -16.9; -19.0; -20.5 Score on scale — p=0.485
Phase 3 N=54 Double-blind, Placebo-Controlled Divalproex Sodium ER in Bipolar I or Bipolar II Depression
Bipolar Disorder
Primary: Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score — -9.64; -5.32 units on a scale
Phase 3 N=488 Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive Disorder
Bipolar Depression · Major Depressive Disorder
Primary: Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score — -18.1; -12.4 score on a scale — p=<0.0001
Phase 2 N=116 A Study of JNJ-55308942 in the Treatment of Bipolar Depression
Bipolar Disorder
Primary: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Week 6 — -16.0; -15.4 Units on a scale — p==0.438
Phase 4 N=32 12- Week Open Label Treatment of Refractory Bipolar Depression
Bipolar Disorder
Primary: Primary Measure:Reduction in Depression Symptoms — 16 participants
Phase 4 N=95 DECIFER: Depression and Citalopram In First Episode Recovery
Schizophrenia · Schizophreniform Disorder
Primary: Calgary Depression Scale for Schizophrenia (CDSS) — 1.93; 2.26; 1.83; 2.58 units on a scale
Phase 4 N=339 A Study Evaluating Duloxetine in Patients Hospitalized for Severe Depression
Major Depressive Disorder
Primary: Change From Baseline to 4 Week Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score — 36.1; 36.0; -20.1; -19.9 units on a scale — p=0.88
N/A N=30 Intensive tDCS for MDD: Feasibility Study
Major Depressive Disorder
Primary: Change in Depressive Symptoms Measured by the Patient Health Questionnaire (PHQ-9) — 21; 31.5 percentage of change
Phase 4 N=122 Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder
Major Depressive Disorder
Primary: Change From Baseline in IDS-SR-10 Engagement — -8.11 score on a scale — p=<0.0001
Phase 4 N=34 Escitalopram in the Treatment of Dysthymic Disorder, Double Blind
Dysthymic Disorder
Primary: Hamilton-Depression Rating Scale (HDRS-24 Items) — 10.88; 16.41 units on a scale — p=0.10
Phase 4 N=59 Desvenlafaxine vs. Placebo Treatment of Chronic Depression
Dysthymic Disorder · Dysthymia · Chronic Depressive Disorder
Primary: Hamilton Rating Scale for Depression (HDRS24) — 14.63; 14.21 units on a scale — p=0.09
Phase 2 N=50 Scopolamine in Bipolar Depression
Bipolar Disorder Depression
Primary: Hamilton Depression Rating Scale Score After Last Treatment — 12.0; 13.0 units on a scale — p=0.3
Phase 2 N=120 A 12-Week, Placebo Controlled Trial of Ziprasidone as Monotherapy for Major Depressive Disorder
Major Depressive Disorder
Primary: Hamilton Depression Rating Scale (HAM-D-17) Scores — 20.1; 19.9; 14.7; 15.6 points
Phase 2 N=204 Study in Major Depressive Disorder With NMRA-335140 (BTRX-335140) vs Placebo
Major Depressive Disorder
Primary: Change From Baseline in Hamilton Depression Rating Scale (HAMD-17) Total Score at Weeks 8 — -9.0; -7.4 Scores on a scale — p=0.121
Phase 4 N=46 Antidepressant Plus Asenapine Versus Antidepressant Plus Placebo for Depression
Major Depressive Disorder Without Psychotic Features
Primary: Change in MADRS Total Score — -14.29; -11.61 units on a scale
Phase 3 N=525 A Phase III Study of SM-13496 in Patients With Bipolar I Depression.
Bipolar Depression
Primary: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 6 — -10.6; -13.6; -12.6 units on a scale — p=0.007
Phase 3 N=211 Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose
Major Depressive Disorder With Mixed Features
Primary: Mean Change From Baseline to the 6-week Study Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Scores — -20.5; -13.0 units on a scale — p=<0.0001
Phase 2 N=102 A Study to Evaluate SAGE-217 in Participants With Moderate to Severe Major Depressive Disorder
Major Depression
Primary: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) - Part A — 92.3 percentage of participants
Phase 3 N=327 A Trial of AXS-05 in Patients With Major Depressive Disorder
Depression · Major Depressive Disorder
Primary: Change in MADRS Total Score From Baseline to Week 6 — 15.91; 12.04 score on a scale — p=0.002
Phase 2 N=150 A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
Depressive Disorder, Major
Primary: Change From Randomization to the End of Treatment Phase (Week 6) in the Bech Melancholia Subscale (Bech) (Items 1, 2, 7, 8, 10 and 13) From the Hamilton Rating Scale for…
Phase 4 N=65 Duloxetine for Chronic Depression: a Double-blind Study
Dysthymic Disorder · Depressive Disorder NOS
Primary: Hamilton Depression Rating Scale (HDRS) - 24 Total Score — 5; 10 Scores on a scale — p=.003
N/A N=2,452 Testing Scalable, Single-Session Interventions for Adolescent Depression in the Context of COVID-19
Depression
Primary: Change in Adolescent Depressive Symptom Severity — 14.31; 14.15; 14.22; 12.57 Score on a scale
Phase 3 N=1,149 A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder
Major Depressive Disorder
Primary: Phase C: Time-to-Relapse by Any Criteria as Defined in Blinded Addendum — 63.0; 63.0 days — p=0.5100